News | Heart Valve Technology | October 18, 2022

U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

Smaller Sheath Simplifies Access and Improves Ease-of-Use

Abiomed’s 14 Fr Impella Low Profile Sheath and dilator set.

Abiomed’s 14 Fr Impella Low Profile Sheath and dilator set. 

 


October 18, 2022 —  The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement of Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr. As a result of its smaller size and other technological advancements, the Low Profile Sheath will facilitate easier Impella insertion and removal, reduce procedural steps and help improve outcomes. 

The Low Profile Sheath is the first sheath specifically engineered to be compatible with the Impella single-access technique, which removes the need for an additional access site. Additionally, it is designed to: 

Simplify access and ease-of-use by eliminating the peel-away sheath and the need for the re-access sheath for patients who are sent to the intensive care unit. 

Further minimize vascular complications and bleeding. 

Facilitate easier delivery into the vasculature with a hydrophilic coated long-taper dilator, reducing the need for multiple steps of serial dilation. 

Facilitate easier management of the patient during heart pump removal and vascular closure because Impella can be removed directly from the sheath without re-wiring. 

“Abiomed’s Low Profile Sheath is a game changing technological achievement that will further improve patient outcomes by making it even easier for physicians to insert, manage and remove Impella heart pumps,” said Chuck Simonton, MD, Abiomed’s chief medical officer. 

Abiomed will begin a phased roll-out of the Impella Low Profile Sheath this quarter. 

For more information: www.abiomed.com


Related Content

News | Heart Failure

June 18, 2024 — As we commemorate Juneteenth 2024, JACC, the flagship journal of the American College of Cardiology, has ...

Home June 18, 2024
Home
News | Heart Failure

June 7, 2024 — Calcific aortic valve disease (CAVD) is the major heart valve disease that afflicts nearly 10 million ...

Home June 07, 2024
Home
News | Heart Failure

June 7, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home June 07, 2024
Home
News | Heart Failure

May 28, 2024 — Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with ...

Home May 28, 2024
Home
News | Heart Failure

May 22, 2024 — New research from The Cooper Institute and partners at University of Texas (UT) Southwestern Medical ...

Home May 22, 2024
Home
News | Heart Failure

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

Home April 30, 2024
Home
News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
Subscribe Now